|Bid||0.0000 x 0|
|Ask||0.0000 x 0|
|Day's Range||0.0350 - 0.0356|
|52 Week Range||0.0315 - 0.0900|
|Beta (5Y Monthly)||1.09|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Richard Hopkins has been the CEO of Zelira Therapeutics Limited ( ASX:ZLD ) since 2018, and this article will examine...
Zelira Therapeutics Ltd (ASX:ZLD, OTCQB:ZLDAF), a global leader in the development of clinically validated cannabis medicines, is pleased to announce it has entered into a binding licensing agreement with Alternative Solutions, a licensed grower, manufacturer and distributor of medical cannabis products in the District of Columbia (Washington DC). Under the agreement, Alternative Solutions will produce and distribute the HOPE™ line of products, Zelira's top-selling treatment developed for autism patients, throughout the legal DC medical cannabis market beginning in Q2 2021.
Zelira Therapeutics Ltd (ASX: ZLD) (OTCQB: ZLDAF), a global leader in the development of clinically validated cannabis medicines, is pleased to announce it has entered into a binding agreement with US-based Cardiovascular Solutions of Central Mississippi to develop products that target symptoms and health risks related to cardiovascular disease and diabetes. According to the Agreement, Zelira will develop exclusively for CVSCM novel, hemp-derived formulations of CBD and other cannabinoids to address a range of therapeutic needs associated with Peripheral Arterial Disease (PAD) and Diabetic Neuropathies (DPN).